Full-Time

Medical Director Infectious Diseases

Celgard

Celgard

201-500 employees

High-performance membranes for energy storage

Compensation Overview

$240k - $250k/yr

+ Performance-based bonus eligibility

Cary, NC, USA

Hybrid

Hybrid work arrangement; travel up to 30%, including international and weekend travel.

PharmD, PhD, MD, Doctor of Osteopathic Medicine (DO)

Category
Biology & Biotech
Required Skills
Data Analysis

Get referred to Celgard

See people who can refer or advise you

Requirements
  • An M.D. or D.O. is required, with specialization in Infectious Diseases strongly preferred; an alternative doctoral degree in a health sciences-related field, such as Pharm.D. or Ph.D., may be considered with demonstrated expertise in antiviral therapeutics and significant clinical practice experience.
  • At least 8 years of experience in the pharmaceutical or biotechnology industry, or a combination of 5 or more years of strong clinical or academic experience with demonstrated industry collaboration, is required.
  • Experience in the infectious disease therapeutic area is required, with expertise in antiviral therapy, herpes simplex virus, transplant infectious diseases, hematopoietic stem cell transplantation, or other immunocompromised patient populations considered highly relevant.
  • Demonstrated ability, or potential, to excel in smaller entrepreneurial organizations is required.
  • Strong statistical knowledge and the ability to interpret study findings and communicate appropriately are required.
  • The ability to prioritize and work in a fast-paced and changing environment is required.
  • Exceptional interpersonal, presentation, and communication skills are required.
  • A strong sense of ethics, compliance, and integrity is required.
  • The ability to travel up to 30%, including international and weekend travel, is required.
Responsibilities
  • Lead the development of the annual medical strategic plan with the Medical Affairs leadership team and in alignment with Research and Development and corporate objectives.
  • Contribute to the medical evidence generation strategy, including real-world evidence, investigator-sponsored studies, and collaborative research efforts designed to address key evidence gaps.
  • Provide medical input into clinical development plans, target product profiles, and lifecycle management strategies across pipeline and marketed products.
  • Build and maintain trusted partnerships with key opinion leaders, academic experts, healthcare providers, patient advocacy groups, and payer decision-makers to inform strategy and generate insights.
  • Serve as an internal medical advisor to cross-functional colleagues and as an infectious diseases medical point of contact for key cross-functional teams and committees.
  • Contribute to business development, corporate venture capital, and open innovation efforts, including scientific due diligence, asset evaluation, and integration of medical insights into opportunity assessments.
  • Contribute to publication strategy development and ensure timely execution of data dissemination plans.
  • Collaborate with Medical Communications to ensure consistent and high-quality scientific communications across congresses, symposia, digital channels, and educational initiatives.
  • Contribute to content review committee medical accuracy and scientific review of promotional and non-promotional materials.
  • Support pipeline planning and early-phase development efforts by providing medical input on target product profiles, data interpretation, and clinical differentiation.
  • Lead the conduct of advisory boards and contribute to diverse insight-gathering activities.
  • Contribute to the medical grant program, including establishing key objectives and participating in review.
  • Partner with Health Economics and Outcomes Research and Market Access to support value-based evidence generation and provide direct medical payer engagement, as appropriate.
  • Collaborate with Field Medical teams to ensure strategic alignment, integrate insights into strategic planning, and support continuous training and relevant content development.
  • Participate in national and regional conferences, meetings, consortia, and other scientific forums to support medical affairs strategic objectives.
  • Provide coaching and leadership to junior team members and direct reports, fostering excellence, collaboration, and continuous development.
  • Contribute to the development of standard operating procedures, best practices, and functional standards to ensure medical activities are executed efficiently, ethically, and compliantly.
  • Support audit readiness and quality improvement initiatives.
  • Monitor the changing healthcare landscape to identify emerging global scientific, clinical, and health policy trends.
Desired Qualifications
  • Infectious Diseases specialization for an M.D. or D.O.
  • Expertise in antiviral therapy, herpes simplex virus, transplant infectious diseases, hematopoietic stem cell transplantation, or other immunocompromised patient populations.

Celgard makes and sells high-performance membrane materials and thin separators used inside batteries, as well as fabrics for outdoor apparel and medical PPE. The membranes sit between battery electrodes to prevent contact while allowing ions to pass, enabling safe and efficient operation in lithium-ion and other chemistries. The company stands out through its Asahi Kasei Group affiliation and strategic alliances (such as with Æsir Technologies) to pursue new battery chemistries, while expanding manufacturing capacity. Its goal is to provide reliable membranes and protective fabrics at scale to support safer, longer-lasting energy storage and protective textiles, and to drive industry growth through collaborations.

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

Charlotte, North Carolina

Founded

N/A

Get referred to Celgard

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Celgard launched new Concord coating capabilities on May 26, 2026, widening product customization.
  • Asahi Kasei opened Charlotte wet-process coating on August 20, 2026, expanding addressable battery demand.
  • Lithion Battery alliance and Toyota-linked North Carolina expansion deepen ESS and EV customer exposure.

What critics are saying

  • Asahi Kasei sold Daramic in December 2025, narrowing separator portfolio and strategic flexibility.
  • Celgard’s 2023–2025 Senior, Targray, and MTI litigation signals persistent IP leakage pressure.
  • Chinese separator rivals can commoditize coated separators, eroding Celgard pricing by 2027.

What makes Celgard unique

  • Celgard invented ceramic-coated separators, still central to lithium-ion safety performance.
  • Charlotte and Concord give Celgard U.S.-based dry-process and wet-process separator capacity.
  • Asahi Kasei’s 2026 North Carolina buildout leverages Celgard’s workforce and installed manufacturing base.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Company News

Shalimar Infotech Pvt Ltd
Aug 26th, 2026
Asahi Kasei unveils new wet-process separator coating line in North Carolina, advancing the company's 40-year North American Battery Separator strategy.

Asahi Kasei unveils new wet-process separator coating line in North Carolina, advancing the company's 40-year North American Battery Separator strategy. 26 Aug 2026 Asahi Kasei held a grand opening ceremony on August 20 for its new Hipore(TM) wet-process lithium-ion battery separator coating line in Charlotte, North Carolina, marking a significant milestone in the execution of the company's North American battery separator strategy. The investment expands production capacity at the company's existing Celgard manufacturing facility, establishing North America-based coating and supply capabilities for its wet-process separator technology. The facility represents the first step toward establishing a regional supply structure for wet-process separators. The investment decision was made in 2023, and commercial production is scheduled to begin in the second half of fiscal 2026. The grand opening coincided with the 40th anniversary of the Celgard manufacturing facility in Charlotte, which has been producing dry-process separators in the United States since 1986. The ceremony brought together local government officials, representatives of Toyota Tsusho Corporation, which has entered into a capacity rights agreement related to the facility, and other stakeholders who supported the project's development. The investment comes as North American battery demand is expected to expand beyond electric vehicles, supported by the increasing deployment of energy storage systems. Although the separator market remains competitive, improving regional market conditions are creating opportunities for suppliers with localized production and responsive supply capabilities. "Opening the Charlotte coating line is a key milestone in establishing our North American supply platform for battery separators," said Ryu Taniguchi, President of Asahi Kasei Battery Separator Corporation. "By leveraging Celgard's experienced workforce and established operations, we are expanding our North American product portfolio to include both dry-process and Hipore(TM) wet-process technologies. Together with our planned separator facility in Canada, this investment will bring production capabilities closer to the region's battery market and position Asahi Kasei to swiftly respond as demand grows across electric vehicles and energy storage systems." Construction of Asahi Kasei's wet-process separator facility in Canada is also progressing according to plan. Together, the Charlotte coating line and the Canadian plant will establish a regional supply framework for wet-process separators, strengthening the company's manufacturing presence and market position in North America. The investments support Asahi Kasei's broader growth strategy for Energy & Infrastructure, which is designated as a Growth Potential area of business under the company's medium-term management plan. About Asahi Kasei Asahi Kasei is a diversified global company that contributes to life and living for people around the world. Since its foundation in 1922, with businesses in ammonia and cellulose fiber, Asahi Kasei has consistently grown through proactive portfolio transformation to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to sustainability by providing solutions to the world's challenges across its three business sectors: Healthcare, Homes, and Material.

Best Magazine
May 26th, 2026
Celgard celebrates 15 years at Concord site, expands separator coating capability.

Celgard celebrates 15 years at Concord site, expands separator coating capability. 26 May 2026 Celgard has launched new coating capabilities at its Concord, North Carolina manufacturing facility as the lithium-ion battery separator manufacturer marked the site's 15th anniversary. The company said the expansion adds new "state-of-the-art" coating technology capable of producing functional coatings, multilayer coated separators (MCS) and other customised separator products for lithium-ion batteries. According to the company, its new capabilities support a range of coating patterns, thicknesses, coverage levels and multilayer structures, while remaining compatible with multiple base-film technologies. The company said this would enable the development of more tailored separator products for electric vehicles, stationary energy storage systems and next-generation battery applications. Celgard's second US manufacturing site. The Concord plant opened in 2011 as Celgard's second US manufacturing site and forms part of the company's North American manufacturing network. The announcement comes amid the separation of Celgard and lead-acid battery separator specialist Daramic following the sale of Daramic by parent company Asahi Kasei. Celgard describes itself as the original inventor of ceramic-coated separators (CCS), a technology widely used in lithium-ion batteries to improve thermal stability and safety performance. "With our global footprint especially deeply rooted in US, we are excited to drive the LIB industry to a new level with our partners," the company said. Photo: Employees at the Concord facility were joined by local business leaders and government representatives for a ribbon-cutting ceremony marking the launch of the new coating capabilities. Credit: Celgard

Yahoo Finance
Jan 29th, 2024
Celgard and Æsir Technologies Forge Strategic Alliance to Drive Industry Innovation in Nickel-Zinc, Zinc-Air and Lithium-Zinc Batteries

Together, Celgard and Æsir will collaborate on joint research projects to further develop high-technology next-generation Nickel-Zinc (Ni-Zn), Zinc-Air (Zn-Air), Lithium-Zinc (Li-Zn) and Sodium-Zinc (Na-Zn) batteries used primarily in aviation, data centers, telecom, energy infrastructure and electric vehicle (EV) charging applications.

Plant Services
Nov 30th, 2023
Celgard expands North Carolina manufacturing plant to support electric vehicle supply chain

Celgard, LLC has announced plans to expand its manufacturing facility in Charlotte, North Carolina, generating 100 new jobs in the process.

PR Newswire
Oct 31st, 2023
Celgard Charlotte Manufacturing Facility To Expand Battery Separator Capacity And Create New Jobs

Celgard to expand facilities, workforce and product portfolio to better serve the EV battery separator supply chain. Post thisThe Biden-Harris Administration and the U.S. Department of Energy (DOE) have identified the domestic U.S. battery market as a critical supply chain focus area for the nation. Investments in Celgard's Charlotte plant will allow the company to expand existing infrastructure to quickly meet demand of the lithium-ion battery (LIB) separator supply chain and domestic customers.Celgard manufactures dry-process membrane separator also used in vehicle electrification. The company already has a skilled employee base capable of applying technical coatings to base film shipped from Hipore™ sister locations and completing finishing steps required to meet customer specifications